Jose J G Marin

List of Publications by Year
in descending order

260	11,858	34105	39675
papers	citations	52 h-index	94 g-index

263	263	263	13087
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155
2	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	17.8	964
3	Bile acids: Chemistry, physiology, and pathophysiology. World Journal of Gastroenterology, 2009, 15, 804.	3.3	427
4	The Antiviral Activities of Artemisinin and Artesunate. Clinical Infectious Diseases, 2008, 47, 804-811.	5.8	425
5	Wntâ€“Î²-catenin signalling in liver development, health and disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 121-136.	17.8	341
6	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	7.3	218
7	Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an â€œin vitroâ€• replicative system. Antiviral Research, 2005, 68, 75-83.	4.1	198
8	Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut, 2013, 62, 899-910.	12.1	163
9	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochemical Journal, 2003, 371, 897-905.	3.7	160
10	Bile Acids in Physiology, Pathology and Pharmacology. Current Drug Metabolism, 2015, 17, 4-29.	1.2	131
11	Carriers Involved in Targeting the Cytostatic Bile Acid-Cisplatin Derivativescis-Diammine-chloro-cholylglycinate-platinum(II) andcis-Diammine-bisursodeoxycholate-platinum(II) toward Liver Cells. Molecular Pharmacology, 2002, 61, 853-860.	2.3	130
12	Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 318-334.	1.7	125
13	Antiviral Effect of Artemisinin from Artemisia annua against a Model Member of the Flaviviridae Family, the Bovine Viral Diarrhoea Virus (BVDV). Planta Medica, 2006, 72, 1169-1174.	1.3	124
14	Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 2013, 58, 1065-1073.	7.3	124
15	Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. Journal of Hepatology, 2006, 44, 1150-1157.	3.7	120
16	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
17	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews, 2012, 44, 148-172.	3.6	117
18	Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. Journal of Hepatology, 1998, 28, 829-839.	3.7	114

#	Article	IF	Citations
19	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	7.3	112
20	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663.	3.7	112
21	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology, 2014, 59, 1972-1983.	7.3	105
22	Expression in Human Trophoblast and Choriocarcinoma Cell Lines, BeWo, Jeg-3 and JAr of Genes Involved in the Hepatobiliary-like Excretory Function of the Placenta. Placenta, 2007, 28, 107-117.	1.5	102
23	Maternal cholestasis during pregnancy programs metabolic disease in offspring. Journal of Clinical Investigation, 2013, 123, 3172-3181.	8.2	92
24	Chemoresistance and chemosensitization in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1444-1453.	3.8	91
25	Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochemical Pharmacology, 2013, 86, 926-939.	4.4	88
26	Rutin has intestinal antiinflammatory effects in the CD4+ CD62L+ T cell transfer model of colitis. Pharmacological Research, 2014, 90, 48-57.	7.1	85
27	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology, 2016, 63, 1287-1298.	7.3	85
28	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83.	3.7	81
29	Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. Placenta, 2006, 27, 34-41.	1.5	80
30	Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Reviews in Molecular Medicine, 2008, 10, e9.	3.9	80
31	Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology, 2012, 425, 31-39.	2.4	80
32	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	17.8	80
33	OATP8/1B3-mediated Cotransport of Bile Acids and Glutathione. Journal of Biological Chemistry, 2006, 281, 30326-30335.	3.4	78
34	Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. International Immunopharmacology, 2013, 15, 372-380.	3.8	76
35	Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochemical Pharmacology, 2006, 72, 729-738.	4.4	74
36	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorganic and Medicinal Chemistry, 2013, 21, 4432-4441.	3.0	74

#	Article	IF	Citations
37	No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors. Molecular Pharmaceutics, 2012, 9, 1693-1704.	4.6	73
38	MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	7.3	72
39	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	3.8	72
40	Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. Journal of Hepatology, 2005, 43, 324-332.	3.7	68
41	Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development. Molecular Cancer Research, 2014, 12, 91-100.	3.4	65
42	Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta. Molecular Pharmacology, 2012, 81, 273-283.	2.3	63
43	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	4.1	63
44	Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. Gut, 1999, 45, 446-452.	12.1	62
45	Molecular bases of the poor response of liver cancer to chemotherapy. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 182-192.	1.5	60
46	Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment. Current Medicinal Chemistry, 2010, 17, 709-740.	2.4	58
47	Effect of Ursodeoxycholic Acid on the Impairment Induced by Maternal Cholestasis in the Rat Placenta-Maternal Liver Tandem Excretory Pathway. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 515-524.	2.5	57
48	Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R1505-R1516.	1.8	57
49	Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs. Current Cancer Drug Targets, 2012, 12, 402-438.	1.6	57
50	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	3.7	56
51	Cisplatin-Induced Chemoresistance in Colon Cancer Cells Involves FXR-Dependent and FXR-Independent Up-Regulation of ABC Proteins. Molecular Pharmaceutics, 2012, 9, 2565-2576.	4.6	55
52	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	12.1	55
53	Excretion of biliary compounds during intrauterine life. World Journal of Gastroenterology, 2009, 15, 817.	3.3	55
54	Inhibition of Na+-Taurocholate Co-transporting Polypeptide-mediated Bile Acid Transport by Cholestatic Sulfated Progesterone Metabolites. Journal of Biological Chemistry, 2010, 285, 16504-16512.	3.4	54

#	Article	IF	Citations
55	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	3.9	54
56	Effect of maternal cholestasis on bile acid transfer across the rat placentaâ€“maternal liver tandem. Hepatology, 2000, 31, 975-983.	7.3	53
57	Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1500, 153-160.	3.8	52
58	Bile acid transport by basal membrane vesicles of human term placental trophoblast. Gastroenterology, 1990, 99, 1431-1438.	1.3	48
59	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-593.	4.3	48
60	Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2212-2219.	4.1	46
61	Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology. BioMed Research International, 2013, 2013, 1-13.	1.9	46
62	A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. Journal of Medical Genetics, 2011, 48, 219-225.	3.2	45
63	Lack of mitochondrial DNA impairs chemical hypoxia-induced autophagy in liver tumor cells through ROS-AMPK-ULK1 signaling dysregulation independently of HIF-1Î±. Free Radical Biology and Medicine, 2016, 101, 71-84.	2.9	45
64	Molecular Bases of Chemoresistance in Cholangiocarcinoma. Current Drug Targets, 2017, 18, 889-900.	2.1	45
65	Evidence for Carrier-mediated Transport of Unconjugated Bilirubin Across Plasma Membrane Vesicles from Human Placental Trophoblast. Placenta, 2002, 23, 527-535.	1.5	44
66	The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacologica Sinica, 2014, 35, 1-10.	6.1	44
67	Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. Journal of Hepatology, 2012, 56, 367-373.	3.7	43
68	ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. Journal of Hepatology, 2017, 66, 581-588.	3.7	43
69	JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16492-16499.	7.1	43
70	Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Hepatology, 1996, 23, 1208-1217.	7.3	42
71	The Hepatobiliary-like Excretory Function of the Placenta. A Review. Placenta, 2003, 24, 431-438.	1.5	42
72	Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the motherâ€placentaâ€foetus trio during cholestasis of pregnancy. British Journal of Clinical Pharmacology, 2015, 79, 316-329.	2.4	42

#	Article	IF	Citations
73	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology, 2019, 69, 1632-1647.	7.3	42
74	Synthesis and Characterization of the New Cytostatic Complexcis-Diammineplatinum(II)â^'Chlorocholylglycinate. Bioconjugate Chemistry, 1997, 8, 453-458.	3.6	41
75	Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. Journal of Hepatology, 1999, 31, 521-528.	3.7	41
76	Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. Journal of Hepatology, 2002, 36, 534-542.	3.7	41
77	Causes of hOCT1â€Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumorâ€Selective Gene Therapy. Hepatology, 2019, 70, 1246-1261.	7.3	41
78	Usefulness of Liposomes Loaded with Cytostatic Bile Acid Derivatives to Circumvent Chemotherapy Resistance of Enterohepatic Tumors. Molecular Pharmacology, 2003, 63, 742-750.	2.3	40
79	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15846-15857.	1.8	40
80	Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver. Journal of Hepatology, 1990, 11, 165-171.	3.7	39
81	Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3. Molecular Pharmacology, 2011, 79, 596-607.	2.3	39
82	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Reviews, 2016, 30, 55-64.	5.7	39
83	Chemosensitization of hepatocellular carcinoma cells to sorafenib by Î²-caryophyllene oxide-induced inhibition of ABC export pumps. Archives of Toxicology, 2019, 93, 623-634.	4.2	39
84	Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800.	5.4	39
85	Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 162-184.	1.7	38
86	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	3.7	38
87	Structural Characterization, Kinetic Studies, and in Vitro Biological Activity of Newcis-Diamminebis-cholylglycinate(O,Oâ€˜) Pt(II) andcis-Diamminebis-ursodeoxycholate(O,Oâ€˜) Pt(II) Complexes. Bioconjugate Chemistry, 2000, 11, 167-174.	3.6	37
88	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	6.4	37
89	Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. Cancers, 2019, 11, 407.	3.7	36
90	Chronic renal failure-induced changes in serum and urine bile acid profiles. Digestive Diseases and Sciences, 2002, 47, 2398-2406.	2.3	35

#	Article	IF	Citations
91	MicroRNAs and cholestatic liver diseases. Current Opinion in Gastroenterology, 2014, 30, 303-309.	2.3	35
92	Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. Cancers, 2020, 12, 2116.	3.7	35
93	Protective effects of phenolic constituents from Cytisus multiflorus, Lamium album L. and Thymus citriodorus on liver cells. Journal of Functional Foods, 2013, 5, 1170-1179.	3.4	34
94	Protective role of biliverdin against bile acid-induced oxidative stress in liver cells. Free Radical Biology and Medicine, 2016, 97, 466-477.	2.9	34
95	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. Journal of Hepatology, 2021, 74, 1429-1441.	3.7	34
96	Diabetes-Induced cholestasis in the rat: Possible role of hyperglycemia and hypoinsulinemia. Hepatology, 1988, 8, 332-340.	7.3	33
97	Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver. Toxicology, 2006, 225, 183-194.	4.2	33
98	Effect of Cantharidin, Cephalotaxine and Homoharringtonine on â€in vitroâ€•Models of Hepatitis B Virus (HBV) and Bovine Viral Diarrhoea Virus (BVDV) Replication. Planta Medica, 2007, 73, 552-558.	1.3	33
99	Overview of the Molecular Bases of Resistance to Chemotherapy in Liver and Gastrointestinal Tumours. Current Molecular Medicine, 2009, 9, 1108-1129.	1.3	33
100	Relationship between Bile Acid Transplacental Gradients and Transport across the Fetal-Facing Plasma Membrane of the Human Trophoblast. Pediatric Research, 1995, 38, 156-163.	2.3	32
101	Diversity of Pharmacological Properties in Chinese and European Medicinal Plants: Cytotoxicity, Antiviral and Antitrypanosomal Screening of 82 Herbal Drugs. Diversity, 2011, 3, 547-580.	1.7	32
102	Nitric oxide mimics transcriptional and post-translational regulation during Î±-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. Journal of Hepatology, 2011, 55, 133-144.	3.7	32
103	Mitochondrial genome depletion dysregulates bile acidâ€•and paracetamolâ€induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. British Journal of Pharmacology, 2011, 162, 1686-1699.	5.4	32
104	Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 547-554.	2.8	31
105	Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta, 2013, 34, 810-816.	1.5	31
106	Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. Journal of Molecular Medicine, 2014, 92, 359-372.	3.9	31
107	Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. Journal of Personalized Medicine, 2018, 8, 14.	2.5	31
108	Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid. PLoS ONE, 2017, 12, e0176504.	2.5	31

#	Article	IF	Citations
109	A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs. Current Drug Delivery, 2004, 1, 275-289.	1.6	30
110	MicroRNAs in biliary diseases. World Journal of Gastroenterology, 2012, 18, 6189.	3.3	30
111	The Expression of Genes Involved in Hepatocellular Carcinoma Chemoresistance Is Affected by Mitochondrial Genome Depletion. Molecular Pharmaceutics, 2014, 11, 1856-1868.	4.6	30
112	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). Journal of Controlled Release, 2015, 216, 93-102.	9.9	30
113	Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2927-2937.	3.8	30
114	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-76.	1.5	29
115	Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. British Journal of Nutrition, 2011, 106, 1814-1825.	2.3	28
116	The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids during maternal cholestasis. Toxicology and Applied Pharmacology, 2014, 277, 77-85.	2.8	28
117	DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. International Journal of Cancer, 1998, 78, 346-352.	5.1	27
118	Overcoming cisplatin resistancein vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. International Journal of Cancer, 2000, 88, 287-292.	5.1	27
119	Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	4.0	26
120	Dual Targeting of G9a and DNA Methyltransferaseâ€1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology, 2021, 73, 2380-2396.	7.3	26
121	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587.	4.3	25
122	FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. Biochemical Pharmacology, 2013, 85, 829-838.	4.4	25
123	Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers, 2019, 11, 1677.	3.7	25
124	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science, 2001, 100, 499.	4.3	25
125	Molecular bases of the fetal liverâ€“placentaâ€“maternal liver excretory pathway for cholephilic compounds. Liver International, 2008, 28, 435-454.	3.9	24
126	What â€œThe Cancer Genome Atlasâ€•database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 577-593.	3.3	23

#	Article	IF	Citations
127	Bile acid secretion during synchronized rat liver regeneration1This study was supported in part by grants SAF94-0693 and SAF96-0146 from the Comision Interministerial Cientifica y Tecnica and grants SA21/96 and SA19/97 from the Junta de Castilla y Leon, Spain.1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1362, 56-66.	3.8	22
128	Leishmania heme uptake involves LmFLVCRb, a novel porphyrin transporter essential for the parasite. Cellular and Molecular Life Sciences, 2020, 77, 1827-1845.	5.4	22
129	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism, 2021, 53, 101275.	6.5	22
130	Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. Journal of Lipid Research, 1998, 39, 1792-1798.	4.2	22
131	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004.	3.7	22
132	Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). Journal of Hepatology, 1998, 28, 417-425.	3.7	21
133	Proapoptotic Effect on Normal and Tumor Intestinal Cells of Cytostatic Drugs with Enterohepatic Organotropism. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 24-35.	2.5	21
134	Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis. Journal of Lipid Research, 2007, 48, 1362-1370.	4.2	21
135	Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. Biochemical Pharmacology, 2007, 73, 1394-1404.	4.4	21
136	Characterisation of the nuclear receptors FXR, PXR and CAR in normal and cholestatic placenta. Placenta, 2011, 32, 535-537.	1.5	21
137	Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: Role of the Akt/mTOR survival pathway and Bcl-2 family proteins. Free Radical Biology and Medicine, 2013, 61, 218-228.	2.9	21
138	The small intestinal mucosa acts as a rutin reservoir to extend flavonoid anti-inflammatory activity in experimental ileitis and colitis. Journal of Functional Foods, 2015, 13, 117-125.	3.4	21
139	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. Inflammatory Bowel Diseases, 2016, 22, 2382-2389.	1.9	21
140	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers, 2020, 12, 2605.	3.7	21
141	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology, 2010, 52, 667-677.	7.3	20
142	Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochemical Pharmacology, 2011, 81, 244-250.	4.4	20
143	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	3.7	20
144	Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1611, 249-257.	2.6	19

#	Article	IF	Citations
145	Physiological characteristics of allo-cholic acid. Journal of Lipid Research, 2003, 44, 84-92.	4.2	19
146	Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 740-750.	2.6	19
147	A GAPDH-Mediated Trans-Nitrosylation Pathway Is Required for Feedback Inhibition of Bile Salt Synthesis in Rat Liver. Gastroenterology, 2014, 147, 1084-1093.	1.3	19
148	Unraveling â€˜The Cancer Genome Atlasâ€™ information on the role of SLC transporters in anticancer drug uptake. Expert Review of Clinical Pharmacology, 2019, 12, 329-341.	3.1	19
149	MRP3â€Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. Hepatology, 2020, 72, 949-964.	7.3	19
150	Expanding the Therapeutic Spectrum of Artemisinin: Activity Against Infectious Diseases Beyond Malaria and Novel Pharmaceutical Developments. World Journal of Traditional Chinese Medicine, 2016, 2, 1-23.	1.9	19
151	Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. Hepatology, 1997, 26, 527-536.	7.3	18
152	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). Journal of Controlled Release, 1999, 57, 161-169.	9.9	18
153	Inhibition of the intestinal absorption of bile acids using cationic derivatives: Mechanism and repercussions. Biochemical Pharmacology, 2007, 73, 394-404.	4.4	18
154	Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. Journal of Lipid Research, 2017, 58, 1903-1915.	4.2	18
155	Hyperglycemia-induced cholestasis in the isolated perfused rat liver. Hepatology, 1991, 14, 184-191.	7.3	17
156	Bile acidâ€“induced modifications in DNA synthesis by the regenerating perfused rat liver. Hepatology, 1993, 18, 1182-1192.	7.3	17
157	Liver Organotropism and Biotransformation of a Novel Platinum-Ursodeoxycholate Derivative, Bamet-UD2, with Enhanced Antitumour Activity. Journal of Drug Targeting, 2001, 9, 185-200.	4.4	17
158	Long-Term Effect of Treating Pregnant Rats with Ursodeoxycholic Acid on the Congenital Impairment of Bile Secretion Induced in the Pups by Maternal Cholestasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 751-758.	2.5	17
159	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	3.1	17
160	Bile acid secretion during rat liver carcinogenesis. Life Sciences, 2000, 66, 1085-1095.	4.3	16
161	Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicology and Applied Pharmacology, 2009, 239, 21-28.	2.8	16
162	Excretion of Foetal Bilirubin by the Rat Placentaâ€“Maternal Liver Tandem. Placenta, 2003, 24, 462-472.	1.5	15

#	Article	IF	Citations
163	Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorganic and Medicinal Chemistry, 2007, 15, 2359-2367.	3.0	15
164	Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3â˜1 and Can 10. Cell and Tissue Research, 2007, 330, 447-460.	2.9	15
165	In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicology and Applied Pharmacology, 2009, 239, 13-20.	2.8	15
166	Strategies for Overcoming Chemotherapy Resistance in Enterohepatic Tumours. Current Molecular Medicine, 2010, 10, 467-485.	1.3	15
167	Plasma Membrane Transporters in Modern Liver Pharmacology. Scientifica, 2012, 2012, 1-15.	1.7	15
168	Effect of pravastatin on the survival of patients with advanced gastric cancer. Oncotarget, 2016, 7, 4379-4384.	1.8	15
169	Role of Genetic Variations in the Hepatic Handling of Drugs. International Journal of Molecular Sciences, 2020, 21, 2884.	4.1	15
170	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-93.	4.3	15
171	Evidence for the presence of carbonic anhydrase in the plasma membrane of rat hepatocytes. Biochimica Et Biophysica Acta - Biomembranes, 1988, 945, 17-22.	2.6	14
172	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science, 2001, 100, 499-508.	4.3	14
173	Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochemical Pharmacology, 2021, 193, 114810.	4.4	14
174	Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clinical Science, 2005, 109, 199-207.	4.3	13
175	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy. Toxicology and Applied Pharmacology, 2008, 232, 327-336.	2.8	13
176	Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2. European Journal of Nutrition, 2014, 53, 401-412.	3.9	13
177	Biopiracy versus One-World Medicineâ€“From colonial relicts to global collaborative concepts. Phytomedicine, 2019, 53, 319-331.	5.3	13
178	Hepatoprotection of Mentha aquatica L., Lavandula dentata L. and Leonurus cardiaca L.. Antioxidants, 2019, 8, 267.	5.1	13
179	Bile secretion by the rat liver during synchronized regeneration. International Journal of Experimental Pathology, 1997, 78, 109-116.	1.3	12
180	Synthesis and characterization of sodium cis-dichlorochenodeoxycholylglycinato(O,N) platinum(II)–cytostatic activity. BioMetals, 1999, 12, 283-290.	4.1	12

#	Article	IF	Citations
181	Predominance of human versus rat phenotype in the metabolic pathways for bile acid synthesis by hybrid WIF-B9 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1534, 45-55.	2.4	12
182	Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver?placenta?maternal liver trio. Journal of Pineal Research, 2007, 43, 130-139.	7.4	12
183	Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland. Scientific Reports, 2017, 7, 7475.	3.3	12
184	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis. International Journal of Molecular Sciences, 2020, 21, 9043.	4.1	12
185	Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. Oncotarget, 2018, 9, 28474-28485.	1.8	12
186	Influence of hydroxylation and conjugation in cross-inhibition of bile acid transport across the human trophoblast basal membrane. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1151, 28-34.	2.6	11
187	Transient changes in the expression pattern of key enzymes for bile acid synthesis during rat liver regeneration. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1734, 127-135.	2.4	11
188	Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R749-R756.	1.8	11
189	Foetal â€˜flatâ€™ bile acids reappear during human liver regeneration after surgery. European Journal of Clinical Investigation, 2009, 39, 58-64.	3.4	11
190	Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget, 2017, 8, 34617-34629.	1.8	11
191	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	3.7	11
192	Impact of Alternative Splicing Variants on Liver Cancer Biology. Cancers, 2022, 14, 18.	3.7	11
193	Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis. Clinical Science, 2002, 102, 143.	4.3	10
194	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death and Disease, 2021, 12, 555.	6.3	10
195	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103.	3.6	10
196	Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs. Frontiers in Bioscience - Landmark, 2009, Volume, 4257.	3.0	10
197	Fetal excretion of the fluorescent bile acid derivative cholylglycylamido-fluorescein (FITC-GC) by the rat placenta-maternal liver tandem. Placenta, 1998, 19, 119-126.	1.5	9
198	Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes. American Journal of Physiology - Renal Physiology, 2008, 295, G54-G62.	3.4	9

#	Article	IF	Citations
199	Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharmacological Research, 2012, 66, 419-427.	7.1	9
200	Role of the placenta in serum autotaxin elevation during maternal cholestasis. American Journal of Physiology - Renal Physiology, 2018, 315, G399-G407.	3.4	9
201	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers, 2021, 13, 2358.	3.7	9
202	Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opinion on Investigational Drugs, 2021, 30, 675-679.	4.1	9
203	Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Cancers, 2021, 13, 5349.	3.7	9
204	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	9
205	Evidence for Dual Effects of DNA-Reactive Bile Acid Derivatives (Bamets) on Hepatitis B Virus Life Cycle in anIn VitroReplicative System. Antiviral Chemistry and Chemotherapy, 2002, 13, 371-380.	0.6	8
206	Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sciences, 2006, 79, 1014-1019.	4.3	8
207	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Digestive Diseases, 2017, 35, 275-281.	1.9	8
208	Dysregulation of autophagy in rat liver with mitochondrial DNA depletion induced by the nucleoside analogue zidovudine. Archives of Toxicology, 2018, 92, 2109-2118.	4.2	8
209	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165687.	3.8	8
210	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-6.	1.5	8
211	Beneficial effect of ursodeoxycholic acid in patients with acylâ€CoA oxidase 2 (ACOX2) deficiencyâ€“associated hypertransaminasemia. Hepatology, 2022, 76, 1259-1274.	7.3	8
212	Influence of Dehydrocholate on Bilirubin Transport into Bile in the Rat. Digestion, 1986, 33, 80-88.	2.3	7
213	Plasma membrane-bound carbonic anhydrase activity in the regenerating rat liver. Biochimica Et Biophysica Acta - Biomembranes, 1991, 1061, 9-14.	2.6	7
214	Relationship Between Tumor Cell Load and Sensitivity to the Cytostatic Effect of Two Novel Platinum-bile Acid Complexes, Bamet-D3 and Bamet-UD2. Journal of Drug Targeting, 2002, 10, 397-404.	4.4	7
215	Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochemical Pharmacology, 2020, 171, 113682.	4.4	7
216	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology, 2021, 73, 186-203.	7.3	7

#	Article	IF	Citations
217	Use of Thermal Fogs of Bioresmethrin and Cismethrin for Control of Periplaneta Americana (Insecta:) Tj ETQq1 1 0.784314 rgBT /Over	1.8	6
218	Effect of streptozotocin-induced diabetes on sex differences in biliary lipid secretion in the rat. Lipids and Lipid Metabolism, 1990, 1043, 106-112.	2.6	6
219	Effect of maternal cholestasis on the kinetics of bile acid transport across the canalicular membrane of infant rat livers. International Journal of Experimental Pathology, 2003, 78, 383-390.	1.3	6
220	Effect of maternal obstructive cholestasis during pregnancy on the biliary transport of horseradish peroxidase in the rat offspring. Clinical Science, 2003, 105, 347-353.	4.3	6
221	Biodetection of potential genotoxic pollutants entering the human food chain through ashes used in livestock diets. Food Chemistry, 2016, 205, 81-88.	8.2	6
222	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 2020, 12, 3748.	3.7	6
223	Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 211-214.	1.5	6
224	Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma. Cells, 2020, 9, 498.	4.1	6
225	Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis. Molecular Therapy - Methods and Clinical Development, 2021, 22, 210-221.	4.1	6
226	Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies. Cancers, 2022, 14, 3455.	3.7	6
227	Role of rate-limiting enzymes of nucleotide metabolism in taurocholate-induced DNA synthesis inhibition. Journal of Hepatology, 1996, 25, 191-199.	3.7	5
228	Characterization of WIF-B9/R cells as an in vitro model with hepatocyte-like polarity and enhanced expression of canalicular ABC transporters involved in phase III of hepatic detoxification. Toxicology, 2007, 232, 24-36.	4.2	5
229	How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. World Journal of Gastroenterology, 2008, 14, 5617.	3.3	5
230	ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds. Biochemical Pharmacology, 2012, 84, 1651-1659.	4.4	5
231	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion on Investigational Drugs, 2021, 30, 377-388.	4.1	5
232	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Reports, 2021, 3, 100276.	4.9	5
233	Further understanding of mechanisms involved in liver cancer chemoresistance. Hepatoma Research, 2017, 3, .	1.5	5
234	Enhanced bile formation induced by experimental dicrocoeliosis in the hamster. Life Sciences, 1998, 63, 1963-1974.	4.3	4

#	Article	IF	Citations
235	Treatment of paediatric cholestasis due to canalicular transport defects: yet another step forward. Gut, 2015, 64, 6-8.	12.1	4
236	Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. Pharmacological Research, 2016, 113, 364-375.	7.1	4
237	In vitro test to determine the effect of cytostatic drugs on co-cultured rat hepatocytes and hepatoma cells. International Journal of Experimental Pathology, 1998, 79, 109-115.	1.3	4
238	Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2)1Part of this work has appeared in abstract form in Hepatology (1996) 24:372A:982.1. International Journal of Pharmaceutics, 1998, 172, 79-88.	5.2	3
239	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	2.5	3
240	Evaluation of the promiscuous component of several bacterial export pumps TolC as a biomarker for toxic pollutants in feedstuffs. Chemico-Biological Interactions, 2019, 305, 195-202.	4.0	3
241	Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma. , 2019, 2, 680-709.		3
242	Evidence for dual effect of bile acids on thymidine anabolism and catabolism by the regenerating rat liver. Biochimica Et Biophysica Acta - General Subjects, 1996, 1289, 136-144.	2.4	2
243	Effect of Bile Acids on Hepatobiliary Transport of Cisplatin by Perfused Rat Liver. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 111-117.	0.0	2
244	Effect of insulin and glucose load on bile lactate secretion by the isolated rat liver. Role of hepatic parenchyma heterogeneity. Biochimica Et Biophysica Acta - General Subjects, 1993, 1158, 8-14.	2.4	1
245	Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP. Annals of Hepatology, 2015, 14, 143-144.	1.5	1
246	PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Journal of Hepatology, 2019, 70, e27-e28.	3.7	1
247	Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer. Pharmacogenomics, 2019, 20, 957-970.	1.3	1
248	Liver and gastrointestinal cancers. , 2020, , 197-250.		1
249	Overcoming cisplatin resistance in vitro by a free and liposomeâ€encapsulated bile acid derivative: BAMETâ€R2. International Journal of Cancer, 2000, 88, 287-292.	5.1	1
250	Bile acid-induced modifications in DNA synthesis by the regenerating perfused rat liver,. Hepatology, 1993, 18, 1182-1192.	7.3	1
251	Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments. Current Women's Health Reviews, 2007, 3, 235-247.	0.2	1
252	Substrate-specific differences in the rate of bile acid carrier reorientation: studies on human placental basal vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1111, 139-141.	2.6	0

#	Article	IF	Citations
253	Chemoprotective Role of Vitamin C in Liver Diseases. , 2018, , 139-153.		0
254	THU-442-Role of drug transporters in the chemoresistance of hepatoblastoma. Journal of Hepatology, 2019, 70, e353.	3.7	0
255	FRI-422-Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells. Journal of Hepatology, 2019, 70, e579.	3.7	0
256	SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e821-e822.	3.7	0
257	PS-011-New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2019, 70, e10.	3.7	0
258	Tuning the intestinal barrier through the neuroendocrine control of ABC pumps expression. Acta Physiologica, 2020, 230, e13544.	3.8	0
259	Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International, 0, , .	1.3	0
260	Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP. Annals of Hepatology, 2015, 14, 143-4.	1.5	0